Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors
Romina Marone, Dominik Erhart, Ann C. Mertz, et al.
Molecular Cancer Research (2009) Vol. 7, Iss. 4, pp. 601-613
Open Access | Times Cited: 113

Showing 1-25 of 113 citing articles:

Targeting PI3K in cancer: mechanisms and advances in clinical trials
Jing Yang, Ji Nie, Xuelei Ma, et al.
Molecular Cancer (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 1308
Targeting metabolic transformation for cancer therapy
Daniel A. Tennant, Raúl V. Durán, Eyal Gottlieb
Nature reviews. Cancer (2010) Vol. 10, Iss. 4, pp. 267-277
Closed Access | Times Cited: 1030
Rapamycin passes the torch: a new generation of mTOR inhibitors
Don Benjamin, Marco Colombi, Christoph Moroni, et al.
Nature Reviews Drug Discovery (2011) Vol. 10, Iss. 11, pp. 868-880
Closed Access | Times Cited: 923
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
William H. Chappell, Linda S. Steelman, Jacquelyn M. Long, et al.
Oncotarget (2011) Vol. 2, Iss. 3, pp. 135-164
Open Access | Times Cited: 549
Rapalogs and mTOR inhibitors as anti-aging therapeutics
Dudley W. Lamming, Lan Ye, David M. Sabatini, et al.
Journal of Clinical Investigation (2013) Vol. 123, Iss. 3, pp. 980-989
Open Access | Times Cited: 487
Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy
Seth A. Wander, Bryan T. Hennessy, Joyce M. Slingerland
Journal of Clinical Investigation (2011) Vol. 121, Iss. 4, pp. 1231-1241
Open Access | Times Cited: 401
Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis
Liesbeth C.W. Vredeveld, Patrícia A. Possik, Marjon A. Smit, et al.
Genes & Development (2012) Vol. 26, Iss. 10, pp. 1055-1069
Open Access | Times Cited: 253
Targeting the mTOR kinase domain: the second generation of mTOR inhibitors
Yan-Jie Zhang, Yan-Wen Duan, Xiao-Feng Zheng
Drug Discovery Today (2011) Vol. 16, Iss. 7-8, pp. 325-331
Open Access | Times Cited: 174
Targeting Fibroblast Growth Factor Receptors Blocks PI3K/AKT Signaling, Induces Apoptosis, and Impairs Mammary Tumor Outgrowth and Metastasis
Julien H. Dey, Fabrizio Bianchi, Johannes Voshol, et al.
Cancer Research (2010) Vol. 70, Iss. 10, pp. 4151-4162
Open Access | Times Cited: 174
mTOR pathway in colorectal cancer: an update
Maria Giovanna Francipane, Eric Lagasse
Oncotarget (2013) Vol. 5, Iss. 1, pp. 49-66
Open Access | Times Cited: 169
PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes
Ipsita Pal, Mahitosh Mandal
Acta Pharmacologica Sinica (2012) Vol. 33, Iss. 12, pp. 1441-1458
Open Access | Times Cited: 158
Coordinate Autophagy and mTOR Pathway Inhibition Enhances Cell Death in Melanoma
Xiaoqi Xie, Eileen White, Janice M. Mehnert
PLoS ONE (2013) Vol. 8, Iss. 1, pp. e55096-e55096
Open Access | Times Cited: 149
Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives
Pei Shi Ong, Louis Z. Wang, Xiaoyun Dai, et al.
Frontiers in Pharmacology (2016) Vol. 7
Open Access | Times Cited: 145
The PTEN–AKT3 signaling cascade as a therapeutic target in melanoma
SubbaRao V. Madhunapantula, Gavin P. Robertson
Pigment Cell & Melanoma Research (2009) Vol. 22, Iss. 4, pp. 400-419
Open Access | Times Cited: 137
The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Induces Tumor Regression in a Genetically Engineered Mouse Model of PIK3CA Wild-Type Colorectal Cancer
Jatin Roper, Michael P. Richardson, Wei Vivian Wang, et al.
PLoS ONE (2011) Vol. 6, Iss. 9, pp. e25132-e25132
Open Access | Times Cited: 126
Dual Inhibition of the PI3K/mTOR Pathway Increases Tumor Radiosensitivity by Normalizing Tumor Vasculature
Emmanouil Fokas, Jae Hong Im, Sally A. Hill, et al.
Cancer Research (2011) Vol. 72, Iss. 1, pp. 239-248
Open Access | Times Cited: 123
Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment
Alberto M. Martelli, Francesca Chiarini, Camilla Evangelisti, et al.
Oncotarget (2012) Vol. 3, Iss. 4, pp. 371-394
Open Access | Times Cited: 119
5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology
Florent Beaufils, Nataša Cmiljanović, Vladimir Cmiljanović, et al.
Journal of Medicinal Chemistry (2017) Vol. 60, Iss. 17, pp. 7524-7538
Open Access | Times Cited: 119
Hesperidin induces apoptosis and triggers autophagic markers through inhibition of Aurora-A mediated phosphoinositide-3-kinase/Akt/mammalian target of rapamycin and glycogen synthase kinase-3 beta signalling cascades in experimental colon carcinogenesis
Saiprasad Gowrikumar, Chitra Palanivel, Ramar Manikandan, et al.
European Journal of Cancer (2014) Vol. 50, Iss. 14, pp. 2489-2507
Closed Access | Times Cited: 103
To Investigate the Occurrence and Development of Colorectal Cancer Based on the PI3K/AKT/mTOR Signaling Pathway
Jiateng Zhong, Shuang Ding, Xinyu Zhang, et al.
Frontiers in Bioscience-Landmark (2023) Vol. 28, Iss. 2
Open Access | Times Cited: 27
Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma
Chintda Santiskulvong, Gottfried E. Konecny, Mirela Fekete, et al.
Clinical Cancer Research (2011) Vol. 17, Iss. 8, pp. 2373-2384
Open Access | Times Cited: 110
Targeting LKB1 signaling in cancer
Susanne E. Korsse, Maikel P. Peppelenbosch, Wendy van Veelen
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2012) Vol. 1835, Iss. 2, pp. 194-210
Open Access | Times Cited: 102
Navigating the Therapeutic Complexity of PI3K Pathway Inhibition in Melanoma
Lawrence N. Kwong, Michael A. Davies
Clinical Cancer Research (2013) Vol. 19, Iss. 19, pp. 5310-5319
Open Access | Times Cited: 87
The Akt signaling pathway
SubbaRao V. Madhunapantula, Paul J. Mosca, Gavin P. Robertson
Cancer Biology & Therapy (2011) Vol. 12, Iss. 12, pp. 1032-1049
Open Access | Times Cited: 86
Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells
Harish C. Pal, Ronald Baxter, Katherine M Hunt, et al.
Oncotarget (2015) Vol. 6, Iss. 29, pp. 28296-28311
Open Access | Times Cited: 82
Page 1 - Next Page

Scroll to top